BioMarin Teams Use Genetic Expertise and Computational Tools to Target More Common Conditions
For geneticist Daniel Gaffney, becoming an expert in how genes influence human health was not enough. His drive to improve lives with this knowledge led him to BioMarin, where he found a shared commitment to translating scientific advances into medicines that solve genetic problems. Since joining the company earlier this year, Dan has helped its […]
A Message from the Chairman and CEO
Dear Stockholder of BioMarin: In 2022, BioMarin achieved record revenue and pivoted to GAAP profitability, making it a truly transformational year for the company and laying the foundation for long-term growth. The global launch of VOXZOGO for children with achondroplasia helped drive that revenue growth. We believe conditional European approval of our gene therapy for […]
Enduring Purpose, Expanding Reach
As we reflect on the progress of the last quarter century, we take this opportunity to also look forward to what’s next for BioMarin. In our continued pursuit to maximize impact for patients, we continue to ask ourselves: what more can we do? The outcome of this ongoing self-assessment has helped bring clarity to how we can best deliver on our purpose – to transform lives through genetic discovery.
Howard University Partners with BioMarin on Regulatory Fellowship
At Howard University, we’re focused on providing our students with valuable experiences that prepare them to become future biopharmaceutical industry leaders. When our College of Pharmacy looked to collaborate with an organization to develop a fellowship in Regulatory Affairs, we wanted a partner that not only thinks strategically about the issues facing the pharmaceutical industry […]